

**PERSPECTIVES**

**SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19**

**Theo A.T.G. van Kempen,<sup>1</sup> and Elisabeth Deixler,<sup>2</sup>**

<sup>1</sup> North Carolina State University, Raleigh, NC, USA.

<sup>2</sup> Independent medical professional, München, Germany

Correspondence: Theo van Kempen (e-mail: [theovankempen@yahoo.com](mailto:theovankempen@yahoo.com))

**RUNNING HEAD**

Running head: COVID-19: influence of phosphate, Mg, and ATP beyond vitamin D

**GRANTS**

This work was pro bono.

**DISCLOSURES**

No conflicts of interest, financial or otherwise, are declared by the authors.

**ADDRESS FOR CORRESPONDENCE**

Theo van Kempen, Alaertslaan 5, 5801DC Venray, the Netherlands

**AUTHOR CONTRIBUTIONS**

E.D. conceived the hypothesis; E.D. and T.v.K. build the total case and manuscript.

## ABSTRACT

**Van Kempen TATG, Deixler E.** SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19. *Am J Physiol Endocrinol Metab* –

The use of vitamin D to reduce the severity of COVID-19 complications is receiving considerable attention, backed by encouraging data. Its purported mode of action is as an immune modulator. Vitamin D, however, also affects metabolism of phosphate and Mg, which may well play a critical role in SARS-CoV-2 pathogenesis. SARS-CoV-2 may induce a cytokine storm that drains ATP whose regeneration requires phosphate and Mg. These minerals, however, are often deficient in conditions that predispose people to severe COVID-19, including older age (especially males), diabetes, obesity, and usage of diuretics. Symptoms observed in severe COVID-19 also fit well with those seen in classical hypophosphatemia and hypomagnesemia, such as thrombocytopenia, coagulopathy, dysfunction of liver and kidneys, neurologic disturbances, immunodeficiency, failure of heart and lungs, delayed weaning from a respirator, cardiac arrhythmia, seizures, and finally multi-organ failure. Deficiencies of phosphate and Mg can be amplified by kidney problems commonly observed in COVID-19 patients resulting in their wastage into urine. Available data show that phosphate and Mg are deficient in COVID-19 with phosphate showing a remarkable correlation with its severity. In one experiment, COVID-19 patients were supplemented with a cocktail of vitamin D<sub>3</sub>, Mg, and vitamin B<sub>12</sub>, with very encouraging results. We thus argue that COVID-19 patients should be monitored and treated for phosphate and Mg deficiencies, ideally already in the early phases of infection. Supplementation of phosphate and Mg combined with vitamin D could also be implemented as a preventative strategy in populations at risk.

## MAIN TEXT

Vitamin D is receiving considerable attention in the fight against COVID-19. Correlations between serum calcifediol and severity of COVID-19 ( $R^2 = 0.96$ ) have been demonstrated with two times higher infection rates for people with low vs. high circulating calcifediol (16, 34), and over 50 clinical trials have been initiated (clinicaltrials.gov, accessed Oct20) to evaluate its impact. The discussion about mode of action focuses foremost on its effect on immunity (31, 34). What we would like to argue is that the more fundamental role of vitamin D in mineral metabolism also should be considered in the etiology of COVID-19. Vitamin D plays an important role in the metabolism of Ca, phosphate (21), and Mg (24), both by stimulating intestinal uptake as well as by preventing renal excretion, while a Mg deficit can also compromise vitamin D status (71). Especially phosphate and Mg are often clinically ignored despite their critical role in energy metabolism, which is clearly perturbed in COVID-19 patients. The role of vitamin D in immunity and its role in mineral metabolism are interconnected and, more specifically, interact via ATP and energy metabolism.

A key deleterious effect of a SARS-CoV-2 infection is the immune hyperreaction and cytokine storm (11). This acute hyperinflammatory response is paramount in the severity of the SARS-CoV-2 infection. Taghizadeh-Hesary and Akbari (58) elegantly explain how SARS-COV-2 may cause a depletion of cellular ATP and a dysfunction of immune cells, and they propose a repletion of cellular ATP to improve the efficiency of the immune system. In line with this, Kouhpayeh et al. (39) propose that SARS-CoV-2 activates PARP-2 (poly [ADP-ribose] polymerase 2), which induces a depletion of  $\text{NAD}^+$  and consequently also drains cellular ATP. Scrutiny of this hypothesis reveals that a critical part of the process may have been overlooked. For the synthesis and regeneration of ATP, phosphate and Mg are required. Due to often diminished food intake during infectious diseases, the higher ATP requirements of activated immune cells are mainly covered by mobilization of its components, like phosphate and Mg, from stored reserves in bones and/or muscles through cytokine release (64). This catabolism in bones and muscles in

response to an inflammatory stimulus supports anabolism in immune cells, but it may also lead to an intracellular decrease of phosphate and ATP and finally to a break-down of muscle cells with release of intracellular phosphate and magnesium into the extracellular space (64). When these nutrients are already in short supply (due to age, diabetes, etc.), either cytokine release and catabolism may be enhanced, or ATP depletion may be severe and impede the immune system (47). The observed cases of rhabdomyolysis in COVID-19 patients (45, 70) may be an indication of intracellular ATP-depletion and perhaps also severe hypophosphatemia (13).

Interestingly, most risk factors for a severe course of COVID-19 are associated with a deficiency of phosphate and/or Mg. For instance, type 2 diabetics [COVID-19 odds ratio (C-OR) 5.02 (26)] are three times more likely to suffer from hypomagnesemia [incidence 14-48% (20)] while the incidence of hypophosphatemia is notably higher [62 vs. 0% for controls (54)]. Especially diabetics with a poor glycemic control are affected, because hyperglycemia leads to a reduced renal re-absorption of phosphate and Mg (51, 65). Diuretics (55) routinely prescribed against hypertension [C-OR 3.99 (26)] diminish Mg [incidence hypomagnesemia 72-100% (19)] and phosphate [incidence hypophosphatemia 12.5% in patients treated with Thiazide (42)] through enhanced renal excretion. Certain anticancer medicines, like Ifosfamide or Imatinib, may cause hypophosphatemia (42). Furthermore, degree of obesity [C-OR 6.92 (26)] is associated with hypophosphatemia [ $r = -0.22$  (23)] and hypomagnesemia [ $r = -0.21$  (57)]. While hypomagnesemia in obesity is mostly associated with low dietary intake (22), hypophosphatemia is multifactorial (66) and even suspected to play a role in the development of obesity by impeding ATP production (48). Overweight, particularly in the elderly, leads to diminished mitochondrial ATP production (approximately -30%) with secondary muscle weakness (53).

Another intriguing observation is that renal phosphate and Mg re-absorption and, consequently, serum phosphate [-20% for men comparing 20 versus 70 years (14)] and cellular Mg [-13% comparing <65 and >65 years, -23% for >65 years with non-insulin-dependent diabetes mellitus (8)] levels decline

with age [age > 53: C-OR 2.59 (26)]. For phosphate, this decline is much stronger in older men than in older women (14), which is in line with COVID-19 complications being more severe in older men. The role of smoking in COVID-19 patients appears more controversial; lung damage from smoking may make people more susceptible, but odds ratios are typically close to 1 [e.g., C-OR 0.63 (26)]. Smoking dose-dependently increases serum phosphate [ $r = 0.67$  (28)] and decreases ATP [by as much as 70% in heart mitochondria (27)]. The usage of proton-pump inhibitors has also been linked to a worse outcome in COVID-19 patients [C-OR 1.79 (41)]; such proton-pump inhibitors are known to diminish intestinal Mg absorption (17). African Americans infected with SARS-CoV-2 have two times higher death rates than white Americans (69), twice the incidence of hypomagnesemia (43), and in about 76% a vitamin D deficiency mainly due to the fact that pigmentation reduces vitamin D production in the skin (25). Seasonal effects showing low levels of serum phosphate [-36% (29); -10% (61)] and Mg [-15% (61)] in the winter, which are possibly linked to seasonally fluctuating vitamin D levels, have also been observed in COVID-19 patients, which would make more severe SARS-CoV-2 complications more likely in the winter. COVID-19 patients often develop renal failure which typically begins with an acute necrosis of the proximal tubule [23% develop kidney injury (9), 75% proximal tubule abnormalities (38)]. Since this is the precise location for phosphate and Mg re-absorption, the patients' phosphate and Mg status worsens by urinary wasting of these electrolytes. A pregnancy complication more common in women with COVID-19 is pre-eclampsia/eclampsia (1, 46), an endothelial disease often accompanied by magnesium and vitamin D deficiency (10, 11).

While Mg deficiency may occur without hypomagnesemia, when present, it is usually indicative of an important systemic Mg deficit (8). Hypophosphatemia can exist when total stores are low, normal, or high. Clinically significant hypophosphatemia, however, tends to occur when there is a total-body deficit of phosphorus. Hypophosphatemia and hypomagnesemia impede ATP production, and hypophosphatemia additionally diminishes 2,3-bisphosphoglycerate in erythrocytes, which is essential

for the release of O<sub>2</sub> from hemoglobin. This leads to hypoxia at a tissue level (36). Complications from hypophosphatemia include thrombocytopenia, coagulopathy, dysfunction of liver and kidneys, neurologic disturbances, immunodeficiency, delayed weaning from a respirator, rhabdomyolysis, failure of heart and lungs, and finally multi-organ failure (36), which are in line with complications observed in COVID-19. Hypomagnesemia can lead to, among others, cardiac arrhythmia and seizures (35), also observed in COVID-19 patients (6, 37, 44). Furthermore, Mg is an important co-factor of membrane ATPases (4, 52) which are involved in the pathogenesis of the acute respiratory distress syndrome (ARDS) (60, 63). This severe complication of COVID-19 is also often associated with a vitamin D deficiency (7, 15).

Intracellular ATP depletion due to low phosphate and Mg may cause cell death by necrosis instead of apoptosis associated with membrane instability and ATP release into the extracellular space (40). Extracellular ATP, however, can function as a danger signal and start an (over)activation of the immune system (30) with the possible consequence of a cytokine storm or ARDS (39, 47, 62). This may be an explanation of why people with diseases associated with pre-existing low ATP and low energy reserves due to diminished phosphate and/or Mg more easily develop severe COVID-19 symptoms, like a cytokine storm and ARDS. ARDS, itself, is also often associated with ATP-deficiency diseases like diabetes, severe burns, or sepsis (15, 50, 60). Cellular ATP depletion and cell death by necrosis with subsequent activation of the immune system are also discussed as a possible pathomechanism of autoimmune diseases and may also explain various autoimmune phenomena in COVID-19, like auto-antibodies against Interferon or the Kawasaki-like syndrome in children (18).

Few have reported phosphate and Mg levels in COVID-19 patients. Xue et al. (68) registered serum phosphate levels of  $1.11 \pm 0.35$  mM in non-critically sick, and  $0.79 \pm 0.29$  mM in severely sick and showed a correlation between lymphocytes and phosphate ( $r = 0.48$ ). Javdani et al. (32) ranked patients for the severity of lung damage and showed that phosphate was the sole assessed parameter assessed that

correlated. Arenas et al. (5) assessed phosphate in infected renal patients and observed lower levels (0.75 mM vs. 1.45 mM) of phosphate. Alkhouli et al. (3) surveyed 14712 patients for which data were not categorized for severity of the infection. An average value of  $1.07 \pm 0.033$  mM was observed in men, and  $1.09 \pm 0.028$  mM in women. Using the reported standard deviations, however, an estimated 38% of the men and 33% of the women were hypophosphatemic using the threshold defined by Pagana (49). Booth et al. (12) assessed many clinical parameters in patients infected with the closely related SARS and showed that 53% had hypophosphatemia, 57% hypomagnesemia, and 70% hypocalcemia.

Tan et al. (59) supplemented COVID-19 patients once daily with a combination of vitamin D<sub>3</sub> (1000 IU), Mg (150 mg), and vitamin B<sub>12</sub> (500 µg); findings were that significantly fewer patients required oxygen support (18 vs. 63%) and/or intensive care support (6 vs. 32%). Our review of available information aligns with this finding. Vitamin D, beyond a role in immunity, can enhance absorption from the intestinal tract and reduce kidney losses of both phosphate and Mg, which may be critical for respiration and energy metabolism. Some kinds of renal proximal tubulopathy (so-called Fanconi syndrome) have already been treated successfully with vitamin D, phosphate and Ca (2), and urinary phosphate and Mg loss in COVID-19 patients may also be reduced by supplementation with vitamin D. Per the above, we would like to suggest that Tan's supplement should be augmented with phosphate, especially in light of the above reported correlations between the severity of COVID-19 and phosphate. This focus on phosphate was also raised by Seers (56) while Mg was raised Wallace (67). For phosphate and magnesium, actual supplementation levels should be guided by the tissue shortages observed. Intriguingly, the rather controversial chloroquine is typically supplied as a phosphate salt (12% P), and doses used [approximately 1 g/d (33)] can supply 10-20% of the recommended dietary intake for phosphate.

*Conclusion*

168        In conclusion, we suggest monitoring and, when deficient, supplementation of vitamin D, Mg, and  
169        phosphate already during the early phase of COVID-19 or as a preventative in populations at risk, as it  
170        may diminish secondary complications.

## REFERENCES

1. **Ahlberg M, Neovius M, Saltvedt S, Soderling J, Pettersson K, Brandkvist C, Stephansson O.** Association of SARS-CoV-2 test status and pregnancy outcomes. *JAMA* 2020. doi: 10.1001/jama.2020.19124.
2. **Ali SA, Tariq M.** Successful treatment of proximal renal tubular acidosis and Fanconi syndrome with vitamin D replacement. *Saudi J Kidney Dis Transpl* 27: 812-815, 2016. doi: 10.4103/1319-2442.185270.
3. **Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL.** Sex differences in case fatality rate of COVID-19: Insights from a multinational registry. *Mayo Clin Proc* 95: 1613-1620, 2020. doi: 10.1016/j.mayocp.2020.05.014.
4. **Apell HJ, Hitzler T, Schreiber G.** Modulation of the Na,K-ATPase by magnesium ions. *Biochem* 56: 1005-1016, 2017. doi: 10.1021/acs.biochem.6b01243.
5. **Arenas MD, Crespo M, Perez-Saez MJ, Collado S, Redondo-Pachon D, Llinas-Mallol L, Montero MM, Villar-Garcia J, Arias-Cabrales C, Barbosa F, Buxeda A, Burballa C, Sans L, Vazquez S, Oliveras A, Mir M, Outon S, Galceran I, Sola E, Sierra A, Barrios C, Rodriguez E, Cao H, Guerri-Fernandez R, Horcajada JP, Pascual J.** Clinical profiles in renal patients with COVID-19. *J Clin Med* 9: 2020. doi: 10.3390/jcm9082665.
6. **Asadi-Pooya AA, Simani L.** Central nervous system manifestations of COVID-19: A systematic review. *J Neurol Sci* 413: 116832, 2020. doi: 10.1016/j.jns.2020.116832.
7. **Bajwa EK, Bhan I, Quraishi S, Matthay M, Thompson BT.** Low vitamin D status occurs in 90% of patients with ARDS and is associated with longer duration of mechanical ventilation. *Am J Respir Crit Care Med* 193: A1846, 2016. doi:

- 194 8. **Barbagallo M, Dominguez LJ.** Magnesium role in health and longevity. In: *Trace*  
195 *elements and minerals in health and longevity*, edited by Malavolta M, and Mocchegiani  
196 E. Cham: Springer International Publishing, 2018, p. 235-264.
- 197 9. **Battle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan**  
198 **S.** Acute kidney injury in COVID-19: Emerging evidence of a distinct pathophysiology. *J*  
199 *Am Soc Nephrol* 31: 1380-1383, 2020. doi: 10.1681/ASN.2020040419.
- 200 10. **Behjat Sasan S, Zandvakili F, Soufizadeh N, Baybordi E.** The effects of vitamin D  
201 supplement on prevention of recurrence of preeclampsia in pregnant women with a history  
202 of preeclampsia. *Obstet Gynecol Int* 2017: 8249264, 2017. doi: 10.1155/2017/8249264.
- 203 11. **Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR,**  
204 **Kutty S.** Cytokine storm in COVID-19-immunopathological mechanisms, clinical  
205 considerations, and therapeutic approaches: The reprogram consortium position paper.  
206 *Front Immunol* 11: 1648, 2020. doi: 10.3389/fimmu.2020.01648.
- 207 12. **Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA,**  
208 **Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski**  
209 **BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW,**  
210 **Poutanen SM, Detsky AS.** Clinical features and short-term outcomes of 144 patients with  
211 SARS in the greater Toronto area. *JAMA* 289: 2801-2809, 2003. doi:  
212 10.1001/jama.289.21.JOC30885.
- 213 13. **Brautbar N, Carpenter C, Baczynski R, Kohan R, Massry SG.** Impaired energy  
214 metabolism in skeletal muscle during phosphate depletion. *Kidney Int* 24: 53-57, 1983.  
215 doi: 10.1038/ki.1983.125.

- 216 14. **Cirillo M, Ciacci C, De Santo NG.** Age, renal tubular phosphate reabsorption, and serum  
217 phosphate levels in adults. *N Engl J Med* 359: 864-866, 2008. doi:  
218 10.1056/NEJMc0800696.
- 219 15. **Dancer RC, Parekh D, Lax S, D'Souza V, Zheng S, Bassford CR, Park D, Bartis DG,**  
220 **Mahida R, Turner AM, Sapey E, Wei W, Naidu B, Stewart PM, Fraser WD,**  
221 **Christopher KB, Cooper MS, Gao F, Sansom DM, Martineau AR, Perkins GD,**  
222 **Thickett DR.** Vitamin D deficiency contributes directly to the acute respiratory distress  
223 syndrome (ARDS). *Thorax* 70: 617-624, 2015. doi: 10.1136/thoraxjnl-2014-206680.
- 224 16. **Davies G, Garami AR, Byers JC.** Evidence supports a causal role for vitamin D status in  
225 global COVID-19 outcomes. *MedRxiv* 2020. doi: 10.1101/2020.05.01.20087965.
- 226 17. **de Baaij JH, Hoenderop JG, Bindels RJ.** Magnesium in man: Implications for health  
227 and disease. *Physiol Rev* 95: 1-46, 2015. doi: 10.1152/physrev.00012.2014.
- 228 18. **Galeotti C, Bayry J.** Autoimmune and inflammatory diseases following COVID-19. *Nat*  
229 *Rev Rheumatol* 16: 413-414, 2020. doi: 10.1038/s41584-020-0448-7.
- 230 19. **George M, Joseph L, Jose CK, James AM, Allan NB, Shaji S.** Effect of Thiazide and  
231 loop diuretics on serum magnesium and other electrolytes in cardiac patients. *J Drug*  
232 *Discovery Therap* 5: 2017.
- 233 20. **Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH.** Hypomagnesemia in type 2  
234 diabetes: A vicious circle? *Diabetes* 65: 3-13, 2016. doi: 10.2337/db15-1028.
- 235 21. **Goretti Penido M, Alon US.** Phosphate homeostasis and its role in bone health. *Pediatr*  
236 *Nephrol* 27: 2039-2048, 2012. doi: 10.1007/s00467-012-2175-z.

- 237 22. **Guerrero-Romero F, Flores-Garcia A, Saldana-Guerrero S, Simental-Mendia LE,**  
238 **Rodriguez-Moran M.** Obesity and hypomagnesemia. *Eur J Intern Med* 34: 29-33, 2016.  
239 doi: 10.1016/j.ejim.2016.06.015.
- 240 23. **Haap M, Heller E, Thamer C, Tschritter O, Stefan N, Fritsche A.** Association of  
241 serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in  
242 non-diabetic subjects. *Eur J Clin Nutr* 60: 734-739, 2006. doi: 10.1038/sj.ejcn.1602375.
- 243 24. **Hardwick LL, Jones MR, Brautbar N, Lee DB.** Magnesium absorption: Mechanisms  
244 and the influence of vitamin D, calcium and phosphate. *J Nutr* 121: 13-23, 1991. doi:  
245 10.1093/jn/121.1.13.
- 246 25. **Harris SS.** Vitamin D and African Americans. *J Nutr* 136: 1126-1129, 2006. doi:  
247 10.1093/jn/136.4.1126.
- 248 26. **Hernandez-Garduno E.** Obesity is the comorbidity more strongly associated for COVID-  
249 19 in Mexico. A case-control study. *Obes Res Clin Pract* 14: 375-379, 2020. doi:  
250 10.1016/j.orcp.2020.06.001.
- 251 27. **Hosseini M-J, Naserzadeh P, Salimi A, Pourahmad J.** Toxicity of cigarette smoke on  
252 isolated lung, heart, and brain mitochondria: Induction of oxidative stress and cytochrome  
253 C release. *Toxicol Environ Chem* 95: 1624-1637, 2014. doi:  
254 10.1080/02772248.2014.884206.
- 255 28. **Hussein S.** Effect of cigarettes smoking on the serum levels of calcium and phosphate in  
256 Sudanese males in Khartoum. *Int J Res Pharm Biosci* 2: 4-9, 2015.
- 257 29. **Iwanami M, Osiba S, Yamada T, Yoshimura H.** Seasonal variations in serum inorganic  
258 phosphate and calcium with special reference to parathyroid activity. *J Physiol* 149: 23-  
259 33, 1959. doi: 10.1113/jphysiol.1959.sp006322.

- 260 30. **Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC,**  
261 **Florquin S, Flavell RA, Leemans JC, Sutterwala FS.** Necrotic cells trigger a sterile  
262 inflammatory response through the NLRP3 inflammasome. *Proc Natl Acad Sci USA* 106:  
263 20388-20393, 2009. doi: 10.1073/pnas.0908698106.
- 264 31. **Jakovac H.** COVID-19 and vitamin D - is there a link and an opportunity for  
265 intervention? *Am J Physiol Endocrinol Metab* 318: E589, 2020. doi:  
266 10.1152/ajpendo.00138.2020.
- 267 32. **Javdani F, Parsa S, Shakeri H, Hatami N, Kalani N, Haghbeen M, Raufi R, Abbasi**  
268 **A, Keshavarz P, Hashemi SA, Shafiee A.** Phosphate levels and pulmonary damage in  
269 COVID-19 patients based on CO-RADS scheme: Is there any link between parathyroid  
270 gland and COVID-19? *MedRxiv* 2020.2008.2025.20181453, 2020. doi:  
271 10.1101/2020.08.25.20181453.
- 272 33. **Karalis V, Ismailos G, Karatza E.** Chloroquine dosage regimens in patients with  
273 COVID-19: Safety risks and optimization using simulations. *Saf Sci* 129: 104842, 2020.  
274 doi: 10.1016/j.ssci.2020.104842.
- 275 34. **Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF.** SARS-CoV-2 positivity rates  
276 associated with circulating 25-hydroxyvitamin D levels. *PLoS One* 15: e0239252, 2020.  
277 doi: 10.1371/journal.pone.0239252.
- 278 35. **Kingston ME, Al-Siba'i MB, Skooge WC.** Clinical manifestations of hypomagnesemia.  
279 *Crit Care Med* 14: 950-954, 1986. doi: 10.1097/00003246-198611000-00008.
- 280 36. **Knochel JP.** Hypophosphatemia. *West J Med* 134: 15-26, 1981.

37. **Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C.** Cardiac and arrhythmic complications in patients with COVID-19. *J Cardiovasc Electrophysiol* 31: 1003-1008, 2020. doi: 10.1111/jce.14479.
38. **Kormann R, Jacquot A, Alla A, Corbel A, Koszutski M, Voirin P, Garcia Parrilla M, Bevilacqua S, Schvoerer E, Gueant JL, Namour F, Levy B, Frimat L, Oussalah A.** Coronavirus Disease 2019: Acute Fanconi syndrome precedes acute kidney injury. *Clin Kidney J* 13: 362-370, 2020. doi: 10.1093/ckj/sfaa109.
39. **Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Zeinalian M, Salari-jazi A, Khanahmad N, Damavandi MS, Sadeghi P, Khanahmad H.** The molecular story of COVID-19; NAD<sup>+</sup> depletion addresses all questions in this infection. *Preprints* 2020030346, 2020. doi: 10.20944/preprints202003.0346.v1.
40. **Le TT, Berg NK, Harting MT, Li X, Eltzschig HK, Yuan X.** Purinergic signaling in pulmonary inflammation. *Front Immunol* 10: 1633, 2019. doi: 10.3389/fimmu.2019.01633.
41. **Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK.** Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. *Gut* Epub ahead of print, 2020. doi: 10.1136/gutjnl-2020-322248.
42. **Liamis G, Milionis HJ, Elisaf M.** Medication-induced hypophosphatemia: A review. *QJM* 103: 449-459, 2010. doi: 10.1093/qjmed/hcq039.
43. **Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, Hutchinson RG, Metcalf PA.** Associations of serum and dietary magnesium with cardiovascular

- disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC study. *J Clin Epidemiol* 48: 927-940, 1995. doi: 10.1016/0895-4356(94)00200-A.
44. **Micke O, Vormann J, Kisters K.** Magnesium deficiency and COVID-19 - what are the links? Some remarks from the German society for magnesium research e.V. *Trace Elem Electrolytes* 37: 103-107, 2020. doi: 10.5414/TEX01651.
45. **Mukherjee A, Ghosh R, Aftab G.** Rhabdomyolysis in a patient with coronavirus disease 2019. *Cureus* 12: e8956, 2020. doi: 10.7759/cureus.8956.
46. **Narang K, Enninga EAL, Gunaratne MDSK, Ibirogba ER, Trad ATA, Elrefaei A, Theiler RN, Ruano R, Szymanski LM, Chakraborty R, Garovic VD.** SARS-CoV-2 infection and COVID-19 during pregnancy: A multidisciplinary review. *Mayo Clinic Proc* 95: 1750-1765, 2020. doi: 10.1016/j.mayocp.2020.05.011.
47. **Nomura J, So A, Tamura M, Busso N.** Intracellular ATP decrease mediates NLRP3 inflammasome activation upon nigericin and crystal stimulation. *J Immunol* 195: 5718-5724, 2015. doi: 10.4049/jimmunol.1402512.
48. **Obeid OA.** Low phosphorus status might contribute to the onset of obesity. *Obes Rev* 14: 659-664, 2013. doi: 10.1111/obr.12039.
49. **Pagana K.** *Mosby's diagnostic and laboratory test reference, 14<sup>th</sup> edition.* St. Louis, Missouri: Elsevier, Inc., 2019.
50. **Patel U, Sriram K.** Acute respiratory failure due to refeeding syndrome and hypophosphatemia induced by hypocaloric enteral nutrition. *Nutr* 25: 364-367, 2009. doi: 10.1016/j.nut.2008.09.011.

- 324 51. **Pham PC, Pham PM, Pham SV, Miller JM, Pham PT.** Hypomagnesemia in patients  
325 with type 2 diabetes. *Clin J Am Soc Nephrol* 2: 366-373, 2007. doi:  
326 10.2215/CJN.02960906.
- 327 52. **Pilotelle-Bunner A, Cornelius F, Sebban P, Kuchel PW, Clarke RJ.** Mechanism of  
328 Mg<sup>2+</sup> binding in the Na<sup>+</sup>,K<sup>+</sup>-ATPase. *Biophys J* 96: 3753-3761, 2009. doi:  
329 10.1016/j.bpj.2009.01.042.
- 330 53. **Potes Y, Perez-Martinez Z, Bermejo-Millo JC, Rubio-Gonzalez A, Fernandez-**  
331 **Fernandez M, Bermudez M, Arche JM, Solano JJ, Boga JA, Oliván M, Caballero B,**  
332 **Vega-Naredo I, Coto-Montes A.** Overweight in the elderly induces a switch in energy  
333 metabolism that undermines muscle integrity. *Aging Dis* 10: 217-230, 2019. doi:  
334 10.14336/AD.2018.0430.
- 335 54. **Revathi R, Amaldas J.** A clinical study of serum phosphate and magnesium in type II  
336 diabetes mellitus. *Int J Med Res Health Sci* 3: 2014. doi: 10.5958/2319-  
337 5886.2014.00005.8.
- 338 55. **Roush GC, Sica DA.** Diuretics for hypertension: A review and update. *Am J Hypertens*  
339 29: 1130-1137, 2016. doi: 10.1093/ajh/hpw030.
- 340 56. **Seers T, Davenport R.** Phosphate metabolism and respiratory alkalosis: A forgotten  
341 lesson in COVID-19. *Age Ageing* 49: 927, 2020. doi: 10.1093/ageing/afaa176.
- 342 57. **Shamnani G, Rukadikar C, Gupta V, Singh S, Tiwari S, Bharti S, Sharma P.** Serum  
343 magnesium in relation with obesity. *Nat J Physiol Pharm Pharmacol* 8, 2018. doi:  
344 10.5455/njppp.2018.8.0104016022018.

58. **Taghizadeh-Hesary F, Akbari H.** The powerful immune system against powerful COVID-19: A hypothesis. *Med Hypotheses* 140: 109762, 2020. doi: 10.1016/j.mehy.2020.109762.
59. **Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, Wong HM, Tern PJW, Chay JWM, Nagarajan C, Sultana R, Low JGH, Ng HJ.** A cohort study to evaluate the effect of combination vitamin D, magnesium and vitamin B<sub>12</sub> (dmb) on progression to severe outcome in older COVID-19 patients. *MedRxiv* 2020.2006.2001.20112334, 2020. doi: 10.1101/2020.06.01.20112334.
60. **Thongprayoon C, Cheungpasitporn W, Srivali N, Erickson SB.** Admission serum magnesium levels and the risk of acute respiratory failure. *Int J Clin Pract* 69: 1303-1308, 2015. doi: 10.1111/ijcp.12696.
61. **Touitou Y, Bogdan A, Haus E, Touitou C.** Modifications of circadian and circannual rhythms with aging. *Exp Gerontol* 32: 603-614, 1997. doi: 10.1016/s0531-5565(96)00161-1.
62. **Trautmann A.** Extracellular ATP in the immune system: More than just a "danger signal". *Sci Signal* 2: pe6, 2009. doi: 10.1126/scisignal.256pe6.
63. **Vadasz I, Raviv S, Sznajder JI.** Alveolar epithelium and Na,K-ATPase in acute lung injury. *Intensive Care Med* 33: 1243-1251, 2007. doi: 10.1007/s00134-007-0661-8.
64. **van Niekerk G, Mitchell M, Engelbrecht AM.** Bone resorption: Supporting immunometabolism. *Biol Lett* 14: 2018. doi: 10.1098/rsbl.2017.0783.
65. **Vorum H, Ditzel J.** Disturbance of inorganic phosphate metabolism in diabetes mellitus: Its relevance to the pathogenesis of diabetic retinopathy. *J Ophthalmol* 2014: 135287, 2014. doi: 10.1155/2014/135287.

- 368 66. **Wagner CA, Imenez Silva PH, Rubio-Aliaga I.** And the fat lady sings about phosphate  
369 and calcium. *Kidney Int* 91: 270-272, 2017. doi: 10.1016/j.kint.2016.11.009.
- 370 67. **Wallace TC.** Combating COVID-19 and building immune resilience: A potential role for  
371 magnesium nutrition? *J Am Coll Nutr* 1-9, 2020. doi: 10.1080/07315724.2020.1785971.
- 372 68. **Xue X, Ma J, Zhao Y, Zhao A, Liu X, Guo W, Yan F, Wang Z, Guo Y, Fan M.**  
373 Correlation between hypophosphatemia and the severity of Corona Virus Disease 2019  
374 patients. *MedRxiv* 2020.2003.2027.20040816, 2020. doi: 10.1101/2020.03.27.20040816.
- 375 69. **Yancy CW.** COVID-19 and African Americans. *JAMA* 323: 1891-1892, 2020. doi:  
376 10.1001/jama.2020.6548.
- 377 70. **Zhang Q, Shan KS, Minalyan A, O'Sullivan C, Nace T.** A rare presentation of  
378 Coronavirus Disease 2019 (COVID-19) induced viral myositis with subsequent  
379 rhabdomyolysis. *Cureus* 12: e8074, 2020. doi: 10.7759/cureus.8074.
- 380 71. **Zittermann A.** Magnesium deficit ? Overlooked cause of low vitamin D status? *BMC*  
381 *Med* 11: 229, 2013. doi: 10.1186/1741-7015-11-229.

382